Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS
PR Newswire•30/10/2026•13:39 ET
0
Key Highlights
- ➤Stryker shares fell $26.70, or 8.8%, wiping out over $10 billion in market capitalization
- ➤Peripheral Vascular manufacturing disruption persisted beyond Q3 and was expected into Q4
- ➤Q2 results disclosed meaningful backorders and lost sales in Peripheral Vascular
- ➤Hagens Berman opened an investigation into Stryker's disclosures and potential securities-law violations
Expert Statements
Kevin Lobo, CEO of Stryker
“I'm not going to get into the details of what it was, but let's just say it did cause a significant backorder specific to one plant in the Inari business”
Kevin Lobo, CEO of Stryker
“The backorder is pretty elevated right now.”
Preston Wells, CFO of Stryker
“not allowing us to reach a full supply of inventory at all of our customers[]”
Preston Wells, CFO of Stryker
“quite frankly, not allowing us to go out and really win new business.”
Preston Wells, CFO of Stryker
“is continuing into the third quarter and will certainly continue – we expect it to continue a little bit into the fourth quarter as well.”
Reed Kathrein, Hagens Berman partner leading the firm's investigation
“We're focused on when Stryker knew its Peripheral Vascular manufacturing problem hadn't been resolved and would persist beyond Q3”
Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS PR Newswire
SAN FRANCISCO, Oct. 30, 2026 /PRNewswire/ -- On September 8, 2026, investors in Stryker Corporation (NYSE: SYK) saw the price of their shares fall $26.70 (-8.8%) after the company's CFO revealed that a previously-thought resolved manufacturing issue persists. The move lower wiped out over $10 billion of Stryker's market capitalization.
Get started
Create a free account to read the full story.